Caas Capital Management LP C4 Therapeutics, Inc. Transaction History
Caas Capital Management LP
- $836 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding CCCC
# of Institutions
122Shares Held
53.8MCall Options Held
331KPut Options Held
145K-
Ra Capital Management, L.P. Boston, MA4.88MShares$29.3 Million0.34% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.85MShares$29.1 Million0.12% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$27.3 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT4.05MShares$24.3 Million1.9% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.56MShares$21.3 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $293M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...